A new round of flu is sweeping in. The world's second largest flu vaccine manufacturer is betting on a rebound in the United States.

The latest performance forecast data from CSL Ltd., the world's second largest influenza vaccine manufacturer, shows that with global health organizations fighting misinformation and the rapid increase in disease incidence closely associated with the latest global influenza season and influenza virus, global health workers' attention to influenza prevention has been renewed, and the scale of influenza vaccine inoculation in the US market is expected to rebound significantly. Dave Ross, General Manager of the vaccine business department Seqirus at CSL, told analysts and investors in Chicago on Tuesday that the US market is expected to experience a significant recovery in the medium term, but he did not provide a specific timetable. Ross emphasized that since the COVID-19 pandemic, misinformation about vaccine safety and efficacy has shaken the global vaccine market, exacerbating people's hesitancy and leading to a significant reduction of about 60 million Americans receiving vaccines each year, as well as an increase in hospitalization rates and the most severe North American flu season in 15 years. Despite this, he stated that more and more professional medical groups and public health advocates are launching top-level medical professional counterattacks, striving to uphold and promote recommendations based on actual vaccine effectiveness and relevant safety evidence. "Science and data will ultimately prevail, and the public health consequences will be too great for us to ignore," Ross said. "Our business, our strategy, and our growth prospects are all very promising to investors." Against the backdrop of a significant decline in flu vaccination rates in the US, this Australia-based global biotechnology leader has postponed its plans to spin off the Seqirus business department for listing, with its stock price even falling to its lowest level in nearly seven years last week. So far this year, the stock has plummeted by about 37% on the Australian stock market, significantly underperforming the local benchmark stock index and healthcare index. The Seqirus business division targets growth in Germany, France, and the Nordic region, helping CSL's vaccine business increase its share of the global seasonal and pandemic influenza vaccine market from about 30% in 2017 to 42% in 2025. The company stated that pre-purchase agreement-related expenses from various government departments will help generate approximately $3.5 billion in revenue during the first wave of influenza vaccine inoculations during the influenza pandemic. CSL Ltd. is a global biotechnology company headquartered in Melbourne, Australia, with three major business segments: CSL Behring focusing on plasma products and biologics in the immunotherapy/coagulation field; Seqirus, the vaccine business, with a core focus on seasonal and pandemic influenza vaccines; and CSL Vifor focusing on drugs for kidney disease, iron deficiency, and other areas. Seqirus is an important business segment of CSL formed after the acquisition of Novartis' influenza vaccine business and the integration of its own vaccine assets, focusing on seasonal influenza and global pandemic influenza vaccines. It has a global market share of about 40%, sharing the flu vaccine market with the leader Sanofi Pasteur under the French pharmaceutical giant Sanofi, which has long held the top market share in the global flu vaccine market. Another major player in the flu vaccine market is the UK pharmaceutical leader GlaxoSmithKline (GSK).